Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 11, 2025
Event: Closing of a previously announced underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational performance metrics. Specific figures include:
- Shares Sold: 28,750,000 shares of common stock.
- Offering Price: $1.00 per share.
- Underwriters' Option: 3,750,000 shares included in the total, exercised in full.
- Net Proceeds: Approximately $26.9 million (after underwriting discounts and estimated expenses).
- Use of Proceeds: Working capital and general corporate purposes.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report.
Material Changes
The primary material change is the increase in the company's share count and cash reserves resulting from the closing of the offering. The transaction was executed pursuant to an existing shelf registration statement (Form S-3, No. 333-268560) filed in November 2022.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize the net proceeds for working capital and general corporate purposes.
Underwriters: Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners; Maxim Group LLC acted as co-manager.
Risks/Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard disclosure that the press release is not deemed "filed" for Section 18 liability purposes unless expressly referenced.
Investor Verification Checklist
- Verify the final number of shares outstanding post-offering in subsequent filings.
- Confirm the actual cash balance increase in the next quarterly report (10-Q) to validate the $26.9 million net proceeds figure.
- Review the attached press release (Exhibit 99.1) for any additional strategic details on the use of proceeds.
- Monitor for dilution impacts on existing shareholders given the issuance of 28.75 million shares.